Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials
- 4 September 2026
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
Abstract
Objective: To evaluate the efficacy and safety of linaclotide in children with functional constipation (FC) by synthesizing evidence from randomized controlled trials (RCTs). Data Sources: A systematic search of PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Google Scholar was conducted from inception through December 2024. The protocol was registered in PROSPERO (CRD420251018285), and the review was performed according to PRISMA guidelines. Study Selection and Data Extraction: RCTs comparing linaclotide with placebo in children (P = .0001) and reduction in straining (MD = −0.26, 95% CI, −0.42 to −0.10; P = .001). No significant effects were observed for spontaneous bowel movement frequency, complete spontaneous bowel movement frequency, or abdominal pain. Treatment-related adverse events were more frequent with linaclotide (relative risk [RR] = 2.93, 95% CI, 1.27-6.77), mainly due to increased diarrhea (RR = 3.81, 95% CI, 1.48-9.82). Relevance to Patient Care and Clinical Practice: Linaclotide may provide symptom relief for selected children with FC, particularly those with hard stools and straining despite conventional therapy. Clinicians should counsel families regarding diarrhea risk and monitor tolerability, while recognizing the limited long-term pediatric evidence. Conclusions: Linaclotide improves stool consistency and reduces straining in pediatric FC but does not consistently improve bowel frequency or global symptom resolution. Its safety profile is generally acceptable, although diarrhea is a notable adverse effect. Further long-term, independently funded trials are needed to define its optimal role in clinical practice.Keywords
This publication has 27 references indexed in Scilit:
- Safety and efficacy of linaclotide in children aged 2–5 years with functional constipation: Phase 2, randomized studyJournal of Pediatric Gastroenterology and Nutrition, 2024
- Randomized controlled trial of linaclotide in children aged 6−17 years with functional constipationJournal of Pediatric Gastroenterology and Nutrition, 2024
- Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialThe Lancet Gastroenterology & Hepatology, 2024
- An Update of Pharmacological Management in Children with Functional ConstipationPediatric Drugs, 2023
- Comprehensive Meta‐Analysis Software2022
- Chronic Functional Constipation in Infants and Children2019
- Management of Functional Constipation in Children: Therapy in PracticePediatric Drugs, 2015
- A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With ConstipationAmerican Journal of Gastroenterology, 2012
- Treatment of Chronic Constipation: Current Pharmacologic Approaches and Future DirectionsClinical Gastroenterology and Hepatology, 2009
- Pilot Study on the Effect of Linaclotide in Patients With Chronic ConstipationAmerican Journal of Gastroenterology, 2008